Phreesia’s (PHR) Buy Rating Reiterated at Canaccord Genuity Group

Canaccord Genuity Group reissued their buy rating on shares of Phreesia (NYSE:PHR) in a report released on Thursday morning,Benzinga reports. They currently have a $16.00 price objective on the stock.

Other equities research analysts have also issued reports about the company. Wall Street Zen upgraded Phreesia from a “hold” rating to a “buy” rating in a research report on Saturday, May 30th. Needham & Company LLC reissued a “buy” rating and set a $14.00 price objective on shares of Phreesia in a research report on Monday, August 31st. Weiss Ratings raised Phreesia from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, July 20th. Piper Sandler cut shares of Phreesia from an “overweight” rating to a “neutral” rating and set a $12.00 target price on the stock. in a report on Thursday, May 28th. Finally, Barclays reaffirmed an “equal weight” rating and issued a $10.00 target price (down from $24.00) on shares of Phreesia in a research report on Thursday, May 14th. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $15.25.

Phreesia Price Performance

PHR stock opened at $10.97 on Thursday. Phreesia has a 1 year low of $7.77 and a 1 year high of $30.43. The company has a market cap of $678.06 million, a P/E ratio of 64.53 and a beta of 0.86. The firm has a 50-day moving average of $11.25 and a 200 day moving average of $10.47. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.76 and a quick ratio of 1.76.

Phreesia (NYSE:PHR) last posted its quarterly earnings data on Wednesday, September 2nd. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.06). Phreesia had a net margin of 2.06% and a return on equity of 5.35%. The firm had revenue of $129.46 million for the quarter, compared to the consensus estimate of $129.06 million. During the same period in the previous year, the firm posted $0.01 earnings per share. The business’s revenue was up 10.4% compared to the same quarter last year. On average, sell-side analysts forecast that Phreesia will post 0.38 EPS for the current year.

Institutional Investors Weigh In On Phreesia

Several hedge funds have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC increased its holdings in shares of Phreesia by 1,119.8% during the first quarter. EverSource Wealth Advisors LLC now owns 3,269 shares of the company’s stock valued at $27,000 after acquiring an additional 3,001 shares in the last quarter. Van ECK Associates Corp boosted its stake in Phreesia by 78.7% in the 4th quarter. Van ECK Associates Corp now owns 2,502 shares of the company’s stock worth $42,000 after purchasing an additional 1,102 shares in the last quarter. New York State Teachers Retirement System bought a new position in Phreesia in the 1st quarter worth about $44,000. Rockefeller Capital Management L.P. grew its position in Phreesia by 354.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 2,755 shares of the company’s stock valued at $47,000 after purchasing an additional 2,149 shares during the last quarter. Finally, Allworth Financial LP purchased a new stake in Phreesia during the 2nd quarter valued at about $58,000. 92.10% of the stock is owned by institutional investors.

Trending Headlines about Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: RBC Capital reiterated a Buy rating on Phreesia, supporting the investment case despite recent earnings pressure. Phreesia Receives a Buy from RBC Capital
• Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating and assigned a $19 price target, while Canaccord Genuity reaffirmed its Buy rating with a $16 target. The targets imply substantial upside from the recent trading level and indicate analysts remain confident in Phreesia’s longer-term prospects.
• Positive Sentiment: Second-quarter fiscal 2027 revenue increased approximately 10% year over year to $129.5 million, slightly exceeding consensus expectations. Adjusted EBITDA reached $32.9 million, highlighting continued operating profitability and scale. Phreesia Q2 Fiscal 2027 Revenue Rises 10 Percent
• Neutral Sentiment: Analyst commentary remains constructive, but the wide gap between current trading levels and price targets suggests the market is waiting for clearer evidence that Phreesia can accelerate earnings growth.
• Negative Sentiment: Phreesia reported quarterly EPS of $0.03, below the consensus estimate of $0.09. The earnings shortfall overshadowed the revenue beat and likely drove the negative investor reaction. Phreesia Shares Sink After 2Q Earnings Underwhelm

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.